2017 American Transplant Congress
Early Steroid Withdrawal and Infection in Kidney Transplant Recipients.
Johns Hopkins School of Medicine, Baltimore, MD
One third of kidney transplant (KT) recipients currently undergo early steroid withdrawal (ESW). Although ESW may slightly increase the risk of rejection in certain subgroups,…2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…2017 American Transplant Congress
Soluble Human Leukocyte Antigen-G Levels and Prolonged Allograft Survival: A Demographic Analysis.
Human leukocyte antigen-G (HLA-G) is a tolerogenic protein shown to contribute to allograft survival. Dimerized, soluble HLA-G (sHLA-Gd) has been shown to significantly prolong allograft…2017 American Transplant Congress
Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan
Background:Safety of everolimus(EVR)when used at an early stage after living donor liver transplantation (LDLT) was proven by many centers including ours. However, the opponents of…2017 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation.
The homing of naïve lymphocytes to the lymph node (LN) is fundamental to the priming of alloreactive T cells. LNs possess highly restricted high endothelial…2017 American Transplant Congress
Tracking the In Vitro Phenotype and Proliferative Capacity of CD57+ CD4 T Cells.
1Duke University, Durham; 2Bristol-Meyers Squibb, Princeton
CD57+PD1- CD4 T cells are primed effectors with increased expression of adhesion molecules capable of infiltrating allografts and mediating belatacept-resistant rejection (BRR). Whether CD57 is…2017 American Transplant Congress
Outcomes with Steroid Avoidance Regimen After Kidney Transplantation without Induction Immunosuppression.
INTRODUCTION: Use of induction immunosuppression therapy at the time of kidney transplantation is variable in low immunological risk kidney transplant recipients. Though acceptable allograft outcomes…2017 American Transplant Congress
Naïve and Interferon-gamma Activated Mesenchymal Stem Cells Differentially Affect Immune Responses In Vitro and In Vivo.
We have observed interferon gamma-treated autologous mesenchymal stem cells (MSC) to rapidly ex vivo expand CD3+CD4+CD25- T cells to >80% CD3+CD4+C25+FoxP3+ T regulatory cells with…2017 American Transplant Congress
Assessment of a Medication Education Program Among New Transplant Recipients at a Large Academic Health Center.
To help patients understand their medications and for adjustment post-transplant, we have implemented a self-medication (self-meds) program as a method of teaching patients their medications…2017 American Transplant Congress
Risk Factors for Cryptococcal Disease in Transplant as Compared with Non-Transplant Patients: A Single Center Study.
Purpose: To examine clinical characteristics of non-HIV, immunocompromised patients diagnosed with cryptococcal disease, including solid-organ transplant (SOT) recipients.Methods: We performed retrospective chart review of non-HIV,…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 138
- Next Page »